Recombinant human erythropoietin (r-HuEPO) is identical to human erythropoietin synthesized in the kidneys, depending on the degree of blood oxygenation. Specifically stimulates erythropoiesis, mitosis and differentiation of erythroid progenitor cells, has an antianemic effect in chronic kidney disease. Increases the number of erythrocytes, reticulocytes, hemoglobin content and hematocrit, improves heart function and tissue blood supply.
Bioavailability after subcutaneous administration is 25%. Maximum concentrationin blood plasma is reached after 12-18 hours. Half-life after subcutaneous administration it is 24 hours, after intravenous administration – 6 hours. With repeated intravenous injections, it does not cumulate. Elimination by the kidneys.
Anemia: in chronic renal failure, hemodialysis, HIV infection during treatment with zidovudine, cytostatic chemotherapy, in premature infants; preparation of patients with anemia for surgery with expected massive blood loss.
Hypersensitivity, uncontrolled arterial hypertension, iron deficiency, pregnancy, breastfeeding.
Gout, history of convulsive reactions, thrombophilia, porphyria.
Pregnancy and lactation:
The category of action on the fetus according to the FDA is C. Contraindicated during pregnancy and lactation.
Method of administration and dosage:
The initial dose is 50 U / kg 3 times a week, if necessary, the dose is increased to 75 U / kg 3 times a week after 1 month; if necessary (resistance) the dose is increased by 25 U / kg every month, but not more than 200 U / kg. The maintenance dose is selected individually, taking into account the hematocrit (but not more than 35 vol.%); after dialysis – 30-100 U / kg 3 times a week.
Arterial hypertension, headache, asthenia, dizziness, arthralgia, chest pain, nausea, vomiting, diarrhea, edema, thrombocytosis, convulsions, skin reactions at the injection site, hyperkalemia, increased levels of creatinine, uric acid and blood urea.
Symptoms: change in hematocrit, polycythemia.
Treatment: temporary discontinuation of the drug until the hematocrit values normalize.
With the simultaneous use of drugs that affect hematopoiesis (for example, iron preparations), the stimulating effect of epoetin beta may increase.
Reduces the plasma concentration of cyclosporine with simultaneous use.